Get started

Biotechnology

SESEN Bio - A possible Jump & Run?The market is bleeding, but may be you know this quote: "Bull markets are born on pessimism, grow on skepticism, mature on optimism, and die on euphoria" - Sir John Templeton So the actual question is, where are we right now? I guess "Euphoria" is actually over and we are on our steady way down to realistic valuations. Let's talk facts: As of March 31, 2022, $SESN had $169.8 million in cash and cash equivalents, no outstanding debt and fewer than 0.2 million outstanding warrants. What is in their pipeline? They are currently developing Vicineum, a locally administered fusion protein, for the treatment of non-muscle invasive bladder cancer (NMIBC). What happened to the stock price? A few months ago the FDA had determined that it cannot approve the BLA for Vicineum in its present form and has provided recommendations specific to additional clinical/statistical data and analyses in addition to Chemistry, Manufacturing and Controls (CMC) issues pertaining to a recent pre-approval inspection and product quality. The stock price dropped dramatically and now trades around 0.50$. What is BLA? BLA, Biologics License Application, is a request for permission to introduce, or deliver for introduction, a biologic product into interstate commerce (21 CFR 601.2). What opportunities lie ahead? Let me tell you, trading bio-tech stocks requires strong guts and control of emotions - I speak from experience. Currently the company is considering two things: 1. Reverse Split, so that they will remain listed on the NASDAQ 2. Selling the company to maximize shareholder value The development of Vicineum will continue and they seek another meeting with the FDA soon to discuss further steps for BLA approval with an additional Phase 3 testing. The 2nd option sounds like a good strategy, the balance sheet looks healthy, the product itself seems promising, so that I had to invest a little bit (10% of my account size). As soon as the company had communicated that they consider selling the company, the stock jumped a nice 30% - luckily I had bought it a few days earlier. Now we can see a little bit of pullback, which seems more like accumulation, rather than distribution. The volume on the declining candles is lower and the strong buy volume after the news actually speaks a different story. You can check my chart for levels (white are monthly and purple are the weekly levels of support and resistance). Let's see what will happen, but the most important thing is patience, as well as proper risk management. Stay healthy!
SLong
by RedFoxTrading
2
$BCTX poised to bounce $BCTX - BriaCell is a cancer treatment biotech that recently dropped 40% AFTER receiving fast track designation for FDA approval. The drop was somewhat coincidental as it's month long bull run finished with a FinTwit pump and dump. BUT the retrace is in and it's approaching historical trend lines and levels of support and looks poised to bounce in the coming week. TD9 is flashing a buy signal, but I wouldn't be shocked if it begins to curl throughout the week. Looking to enter a long swing trade to ride it back to previous highs.
NASDAQ:BCTXLong
by runawaysun
1
$SRRA Long term PTs 79-145 and higher...Parabolic! (HCW)Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.
SLong
by BADQOMOCAWGOWLD
First Solar LONG, ACCUMULATE , HOLD. Great investmentFIRST SOLAR (FSLR). A company with 8,941.60 M of market cap. Good prospects for LONG. After 5 months of retracement from the price of $ 125 to a price of $ 62.5 with an approximate 50% correction we have seen these signals of LONG and open bullish positions. 1) Historically upward trend 2) RSI crossing UP 50% 3) Moving averages 100 and 200 aligned which are acting as a solid support 4) Support of the maximum 2019. Our TP between $ 182 and $ 216, currently approximating $ 200 do you want to know some more INFO? Contact us privately for any information LPI.sa
NASDAQ:FSLRLong
by LPI_Investments
Elevation Oncologys personalised treatment plans for cancer ⚕️I find that the cash ($146M) vs valuation (55M) is rocket fuel for “the herd”. Also presenting itself as an “undiscovered gem” may contribute to a good ol’ pop. They have good social media skills and their website is gorgeous. Being that this will be about as much DD as the masses ever do it can and most times is quite important for fueling said pop. RSI in the low lows lends a little more to the “undiscovered gem” ideology even though I loath technical analysis many do not. News about their phase II study (which they seem to be taking very seriously) should come to light within the following months and as any biotech investor knows: news + biotech = insane short term gains. Check out my ideas on Utradea
NASDAQ:ELEVLong
by Magnus_Chimpski
Allarity priming itself for a pumpAs with most micro biotech companies, I expect the price to continue to fall to the $1 region and then “flatten out” for a while to keep its head just above the minimum listing requirement. It will then probably remain there until it is seemingly forgotten. Then, in a move to regain compliance (if it falls below $1) we can expect some financial reorganisation on the stocks behalf and possibly a R/S on the cards if things get dire. If it remains over the minimum listing price, I expect some group of pumpers to catch on to Allarity and we could see a few weeks of growing buzz on social media platforms, followed by some handy articles and a sudden parabolic move upwards on news as FOMO kicks in to the herd.
NASDAQ:ALLR
by Magnus_Chimpski
ATOS Weekly Shaping UpWe can see that the weekly chart is showing some exhaustion on the sell pressure. The daily has a bit of a heartbeat today breaking over the 20ema/ma. Looking to see the weekly SARs flip underneath to support price, and a break over the T Line (EMA8) on the weekly to confirm a trend change. If there is a solid break, targets (based on current price but will change) would be: Weekly 20ema - 2.04 Weekly 50ema - 2.53 Weekly 100ema - 3.24 Anything over would just be cream. Unless they finally go phase 3 for endoxifen, but I'm sticking to TA.
NASDAQ:ATOSLong
by DrDank
1
$APM Target PTs 7-14 Long term PT 30 and higherAptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer The FDA has granted Orphan Drug Designation to Aptorum Group Limited (NASDAQ: APM) SACT-1, a repurposed small molecule compound for Neuroblastoma. Aptorum Group plans to file an Investigational New Drug Application (IND) to commence a Phase 1b/2a trial for SACT-1 in 2022. Neuroblastoma is one of the most prevailing solid tumor cancers in children, representing 8% - 10% of all childhood tumors, accounting for around 15% of all cancer-related deaths in the pediatric population. Aptorum received its first US patent regarding SACT-1 repurposed drug for various cancers earlier this week. The SACT-1 invention provides a composition and method for treating or preventing the growth of cancerous tumors and/or delaying the onset of cancer from tumor-initiating cells. Price Action: APM shares are up 30.3% at $1.59 during the premarket session on the last check Thursday. See more from Benzinga FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors EXCLUSIVE: Alfi Inks AI Tech Deal For Improved Passenger Experience At BWI Thurgood Marshall Airport
NASDAQ:APMLong
by BADQOMOCAWGOWLD
1
Bayer AG (BAYN.de) bullish scenario:The technical figure Channel Down can be found in the German company Bayer AG (BAYN.de) at daily chart. Bayer AG is a German multinational pharmaceutical and life sciences company and one of the largest pharmaceutical companies in the world. Bayer's areas of business include pharmaceuticals; consumer healthcare products, agricultural chemicals, seeds, and biotechnology products. The company is a component of the Euro Stoxx 50 stock market index. The Channel Down has broken through the resistance line on 12/01/2021, if the price holds above this level you can have a possible bullish price movement with a forecast for the next 49 days towards 54.270 EUR. Your stop loss order according to experts should be placed at 43.905 EUR if you decide to enter this position. Bayer AG on Monday struck a partnership deal with Mammoth Biosciences to develop therapeutic tools based on CRISPR/CAS9 gene editing as the German drug maker seeks to widen its cell and gene therapy development efforts. Unlisted U.S. biotech firm Mammoth will initially receive $40 million from Bayer plus potential milestone payments of more than $1 billion contingent on scientific and commercial achievements. The initial focus of the collaboration will be liver-based diseases, the companies said in a joint statement on Monday. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
XETR:BAYNLong
by legacyFXofficial
$KPRX Target PT 2 and higherKiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference Salt Lake City, Utah--(Newsfile Corp. - January 5, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will participate in the H.C. Wainwright Bioconnect Virtual Conference January 10-13, 2022. Brian Strem, Ph.D., President and Chief Executive Officer, will provide an outlook for the business and its pipeline of treatments for ophthalmic diseases. The corporate presentation will be available on-demand and accessible from the Company's Investor Relations website starting Monday January 10, 2022 at 7:00 am Eastern Time. ​​About Kiora Kiora is a clinical-stage biotechnology company developing and commercializing products for treating ophthalmic diseases. KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and/or age-related retinal degeneration. KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase ("DHODH") with best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with other DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing. For more information, please visit www.kiorapharma.com. Forward-Looking Statements Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 25, 2021 or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.
NASDAQ:KPRXLong
by BADQOMOCAWGOWLD
AEZS European approval to market MacrillenAEterna has a variety of new products in its pipeline. Macrilen, for example, is the first and only FDA-approved oral test for the diagnosis of Adult Growth Hormone Deficiency. AEterna received European approval to market Macrillen. Dr. Christian Strasburger: "Clinical studies have demonstrated that macimorelin is safer and much simpler to administer than the current methods of testing for insulin-induced hypoglycemia, and is well-tolerated by patients and reliable in diagnosing the condition.” I think AEZS is a sleeping giant. My price target is $1.25.
ALong
by TopgOptions
Humanigen is ready to reverseHumanigen's stock has two lower trend resistance lines with price targets of $3 and $2, respectively. The first resistance line has just hit after a month of major events. Catalyst 1: Marc Bistricer of Murchison and Nomis Bay bought back in after major selling over the past year. Catalyst 2: 7 corporate insiders including the CEO (Cameron Durrant) and Chief Scientific Officer (Dale Chappell) announced taking sizable call options at strikes between $0 and $2.85 in lieu of salary. Catalyst 3: Bad news is out and priced in (or largely priced in). The FDA and MHRA have both informed HGEN that its applications to license lenzilumab, the company's proprietary anti-cytokine-storm therapeutic, are delayed pending further data on efficacy, safety, and manufacturing. Catalyst 4: In December the findings from the 2020-2021 LIVE-AIR trial were published in The Lancet, one of the top 5 medical journals in the world. Catalyst 5: the confirmatory ACTIV-5 BET trial sponsored by the NIH is now fully enrolled. The interim data readout is expected at the very earliest in late February, at the latest in early March. The FDA and MHRA will ultimately decide whether to give emergency authorization for lenzilumab as a COVID therapeutic based on the ACTIV-5 results.
HLong
by decaro
1
Record financials warrant a re-ratingQ3 2021 results warrant a re-rating of this $30M mkt cap biotech play: - Revenue was $25.3 million in the third quarter of 2021, up 575%, compared to $3.7 million over the prior three-month period ending June 30, 2021. - Gross profit was $10.5 million in the third quarter of 2021, up 1,288%, compared to $753,535 over the prior three-month period ending June 30, 2021. - Net income was $6.8 million in the third quarter of 2021, compared to a net loss of $8.7 million over the prior three-month period ending June 30, 2021.
MLong
by wealth_bakery
3